We are live on ! Find out more
OTLK icon

Outlook Therapeutics

20 hedge funds and large institutions have $2.17M invested in Outlook Therapeutics in 2020 Q2 according to their latest regulatory filings, with 6 funds opening new positions, 10 increasing their positions, reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

9% less funds holding

Funds holding: 22 → 20 (-2)

18.5% less ownership

Funds ownership: 19.86% → 1.36% (-18%)

33% less first-time investments, than exits

New positions opened: 6 | Existing positions closed: 9

85% less capital inflows, than outflows

Capital inflows: $422K | Capital outflows: $2.91M

100% less funds holding in top 10

Funds holding in top 10: 1 → 0 (-1)

Holders
20
Holders Change
-2
Holders Change %
-9.09%
% of All Funds
0.41%
Holding in Top 10
–
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-100%
% of All Funds
–
New
6
Increased
10
Reduced
–
Closed
9
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

OTLK Hedge Fund Activity: Q2 2020 in Review

20 of the 4,888 institutional investors tracked by Wall St. Rank reported a position in Outlook Therapeutics (OTLK) for Q2 2020, worth a combined $2.17M — down 40% from $3.6M a quarter earlier.

Sellers outnumbered buyers: 9 funds closed out of OTLK and 6 opened new positions — a net loss of 3 holders — while 0 trimmed existing stakes and 10 added.

The largest buyer was LVW Advisors, adding an estimated $213K. The largest seller was Sabby Management, exiting entirely with an estimated $1.94M sold.

  • 20 institutional investors held Outlook Therapeutics (OTLK) as of Q2 2020, down from 22 in Q1 2020.
  • Funds reported $2.17M of Outlook Therapeutics stock for Q2 2020, down 40% quarter-over-quarter.
  • 6 funds opened new Outlook Therapeutics positions in Q2 2020 and 9 closed out, a net change of -3 holders.
  • The largest Outlook Therapeutics buyer in Q2 2020 was LVW Advisors, an estimated $213K added.
  • The largest Outlook Therapeutics seller in Q2 2020 was Sabby Management, an estimated $1.94M sold.

Based on aggregated 13F filings for Q2 2020.